Cannabis-Based Drug Kills 100% of Pancreatic Cancer Cells in New Study

Source: VeriHeal.com | Author: Chane Leigh | Sep 4, 2022

New cannabis research found that a cannabis-based drug was able to kill pancreatic cancer cells. This cannabis-based drug, or rather miraculous medication, is a botanical combination of extracts from the Cyathus striatus fungus and cannabis. This powerful combo was even able to destroy all of the cancer cells without damaging any healthy cells, unlike conventional cancer treatments.

What Is Cyathus striatus Fungus?

Cyathus striatus fungus is otherwise known as a fluted bird’s nest as a result of being a “group of gasteromycetes group of mushrooms named for their similarity in shape to small bird’s nests.” These fungi are generally considered to be inedible but not poisonous “due to their tiny size,” which is also why they are easy to miss in nature.

Cannabis-Based-Drug-Kills-100%-of-Pancreatic-Cancer-Cells-in-New-Study-2

Researchers Waill Elkhateeb and Ghoson Daba explain that this group of mushrooms has been able to “produce many novel and potent secondary metabolites that exerted different bioactivities especially as antimicrobial, antitumor, and anti-neuro inflammation activities.” The fungi found on Cyathus are saprophytes, microorganisms that live on dead organic matter. They are most commonly seen during autumn but can also be found year-round in damp and shady locations.

In their study on bird’s nest fungi, Elkhateeb and Daba explain that the “anti-inflammatory, antimicrobial and antitumor compounds isolated from these mushrooms belong to different chemical classes including steroids, terpenes, polysaccharides, fatty acids, phenolic acids and other metabolites.” However, much like cannabis, they concluded that information on these mushrooms is still unclear and that further research and investigation are needed.

Cyathus and Cannabinoids: The Cancer-Cell-Killing Duo

The treatment was developed by the biomedical company known as Cannabotech, while the study was led by Professor Faud Fares (a senior cancer researcher at the University of Haifa). The fungus was used based on the fact that it has been the subject of eight years of testing for anti-cancer properties, during which it demonstrated to have better anti-cancer results than most other fungi that were being tested.

According to PR Newswire, which reported the news from Cannabotech, the researchers made use of a cell model in order to experiment with their killer combo in order to see if it had any desirable effects on cancer cells—which it did. The cannabinoid and fungus extract duo was able to eliminate 100% of the pancreatic cancer cells in the model and it did so without damaging normal cells.

Since the Cyathus striatus fungus demonstrated better anti-cancer properties in comparison to other fungi, Fares was able to secure global and exclusive rights to use for patents he created. The professor began leading the study in an “accelerated process of developing a botanical drug as defined by the FDA.”

Cannabotech reported that the first milestone in the botanical drug development process was “defined as the adaptation of fungal growth and extraction methods to the FDA protocol for botanical drug development, which the company expects to be significantly cheaper and shorter than the development process of a standard ethical drug.” Then, the combination of the cannabinoid and fungal extract composition was examined.

The researchers were pleased to report that their cell model trial with the adapted extract was able to demonstrate five times higher anti-cancer efficacy than their original extract on top of “causing 100% mortality of pancreatic cancer cells.” They reported that they observed no damage to healthy cells in the model and that the cannabinoid extract was responsible for an 80% mortality of pancreatic cancer cells.

The team plans to complete the feasibility part of the study within 12 months (by mid-2023) and will then work with a large pharmaceutical company for its development. As part of their next milestone, the team plans to test both “the active mechanism of killing cancer cells by extracts and the combined anti-cancer efficacy of the fungus and cannabinoids together, in cells and animals.” The development of this revolutionary drug will be accompanied by Dr. Yitzhak Angel, who is a pharmacologist specializing in drug development with more than 35 years of experience.

The Stakes Are High

There are many types of fatal cancers, but pancreatic cancer is one of the most aggressive, with a very low survival rate- contributing to very high rates of mortality. So having a potential treatment for this cancer creates heaps of possibilities for other forms too. Fares stated:

“I am happy that the collaboration with Cannabotech is bearing fruit and achieving very impressive results to strengthen the research we conducted at the University of Haifa in recent years. The fact that such impressive results have been obtained in cells that mimic a subtype of pancreatic cancer that is known to be highly aggressive, reinforces the assessment that anti-cancer activity will be effective in other subtypes of pancreatic cancer as well.”

Angel, the pharmacologist consultant for Cannabotech, stated that “developing a botanical drug is a challenging process and the results we have achieved are a real indication that the extracts are effective and safe to use as an anti-cancer treatment for pancreatic cancer. We still have a way to go to substantiate that expectation, but we have good hopes to deliver real news to patients and develop a concrete solution to one of the most aggressive cancers.”

Considering the number of lives claimed by cancer and the amount of cancer-causing risks that surround us each day, research like this provides hope and comfort for those with cancer as well as those who are at high risk of developing cancer. Not only is this potential cannabis cure botanical, but it is also shaping up to be a safer and less risky treatment—which is important considering the harsh side effects associated with current cancer treatments.

Samuel Smiles, a cancer patient, stated, “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind it”—and this research is hope.

Cannabis-based colon cancer treatment kill 90% of deadly cells

A new study performed by Cannabotech has demonstrated that the company’s range of Integrative-Colon products may be an effective colon cancer treatment, killing 90% of colon cancer cells in a cell model study.

Source: HealthEuropa.eu | Author: HealthEuropa | Mar 17, 2022

Cannabotech is a biotechnology company pioneering oncological products comprised of cannabis and mushroom extracts. In a recent cell model study, the company has demonstrated that its Integrative-Colon products, which are based on an array of cannabinoids from the cannabis plant and various mushroom extracts, eliminated over 90% of colon cancer cells. The findings offer an exciting prospect for the future of colon cancer treatment.

How did the Integrative Colon products perform?

For their study, the researchers analysed the effectiveness of the Integrative Colon products on a range of colon cancer subtypes, representing different molecular changes that a prevalent in these cancer subtypes. The team compared the composition of the products with the activity of each cannabinoid individually.

The results suggested that the composition of the Integrative Colon products was more effective than each cannabinoid individually, highlighting a strong synergy between the active ingredients. These findings back up claims from Cannabotech that to achieve an effective cannabis colon cancer treatment, it is essential to amalgamate a defined, accurate, and science-based formula that cannot be achieved in any cannabis strain that exists in nature.

Additionally, the study showed the different effects of each cannabinoid on distinct colon cancer subtypes. This echoes the essential need for a individualised approach for patients’ health needs, such as the personalised technology already developed by Cannabotech that will soon hit the market in the UK, US, and Israel at the end of 2022.

The mushroom extracts in the products contain an enriched and high concentration of an active substance called PSK that is extracted from the Trametes mushroom. PSK is known for its anti-cancer properties and has been approved as an oncology treatment in Taiwan, Japan, and South Korea.

Future steps

The researchers are now looking to assess the effectiveness of the formula in combination with standard chemotherapies. In addition, the team plan to combine the cannabinoid formula with the mushroom Cyathus Striatus as part of the botanical drug development project.

Elhanan Shaked, the CEO of Cannabotech, commented: “This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment to reduce its side effects. Cannabotech’s solutions will be launched in Israel and the US towards the second half of 2022, while the company’s goal is to define a new standard for the medical cannabis industry.”

Professor Tami Peretz, Senior Oncologist, said: “Colon cancer is one of the most common tumours today, with a significant proportion of patients currently treated with integrative therapies, in combination with traditional methods, including the administration of medical cannabis. Cannabotech’s Integrative products are unique in that they are designed to standards similar to those of the pharmaceutical industry and incorporate many active ingredients. The company’s products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory. Based on these experiments, there is room to perform animal studies and, in the future, to examine the possibility of incorporating these products in colorectal cancer patients.”

Isaac Angel, Cannabotech’s pharmacological consultant, said: “The significant synergistic effect demonstrated by the combination of active ingredients eliminated over 90% of all types of cancer cells used in the study. Furthermore, this was achieved without the presence of THC, which is the cannabinoid substance producing the “high” effect, whereas each of the other cannabinoids tested individually demonstrated different effects on the various cell types. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products and highlight the need for medical care customisation. We shall continue to work to provide a cure for patients.”